HLS Therapeutics Inc. (HLTRF)

Market Cap	114.49M
Revenue (ttm)	56.77M
Net Income (ttm)	-17.99M
Shares Out	n/a
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	924
Open	3.660
Previous Close	n/a
Day's Range	3.660 - 3.660
52-Week Range	2.220 - 3.660
Beta	1.03
RSI	64.13
Earnings Date	May 8, 2025

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care de...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Craig Millian
• Employees: 92
• Stock Exchange: OTCMKTS
• Ticker Symbol: HLTRF

Financial Performance

In 2024, HLS Therapeutics's revenue was $56.62 million, a decrease of -10.23% compared to the previous year's $63.07 million. Losses were -$19.66 million, -28.61% less than in 2023.